Zurcher Kantonalbank Zurich Cantonalbank Buys 209 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 139,958 shares of the biopharmaceutical company’s stock after buying an additional 209 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned about 0.13% of Regeneron Pharmaceuticals worth $99,696,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of the stock. Sound View Wealth Advisors Group LLC lifted its stake in Regeneron Pharmaceuticals by 9.0% in the fourth quarter. Sound View Wealth Advisors Group LLC now owns 2,227 shares of the biopharmaceutical company’s stock valued at $1,586,000 after buying an additional 183 shares in the last quarter. American Assets Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $427,000. AlphaQuest LLC lifted its position in shares of Regeneron Pharmaceuticals by 13.3% in the fourth quarter. AlphaQuest LLC now owns 2,236 shares of the biopharmaceutical company’s stock worth $1,593,000 after purchasing an additional 262 shares in the last quarter. M. Kulyk & Associates LLC bought a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter worth $1,538,000. Finally, Ellerson Group Inc. ADV lifted its position in shares of Regeneron Pharmaceuticals by 0.9% in the fourth quarter. Ellerson Group Inc. ADV now owns 6,920 shares of the biopharmaceutical company’s stock worth $4,929,000 after purchasing an additional 59 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on REGN shares. Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 17th. They set a “hold” rating and a $165.00 target price on the stock. Citigroup lowered their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $762.00 to $834.00 in a report on Wednesday, February 5th. Robert W. Baird decreased their price objective on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. Finally, Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Trading Up 1.3 %

REGN opened at $707.51 on Monday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $642.00 and a twelve month high of $1,211.20. The company has a 50-day simple moving average of $696.12 and a 200 day simple moving average of $848.69. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $77.35 billion, a price-to-earnings ratio of 18.48, a P/E/G ratio of 2.34 and a beta of 0.27.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analysts’ expectations of $3.76 billion. During the same quarter in the prior year, the business posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.